Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3Terminated 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × GSK2141795 × Clear all
NCT01958112 2019-05-31

GSK1120212+GSK2141795 for Cervical Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
14 enrolled 10 charts
Gynecologic

Uterine Cervical Neoplasms

NCT01907815 2018-04-06

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Terminated
24 enrolled 6 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡